Fluid-Filled Versus Gas-Filled Intragastric Balloons as Obesity Interventions: a Network Meta-analysis of Randomized Trials

  • Fateh Bazerbachi
  • Samir Haffar
  • Tarek Sawas
  • Eric J. Vargas
  • Ravinder Jeet Kaur
  • Zhen Wang
  • Larry J. Prokop
  • M. Hassan Murad
  • Barham K. Abu Dayyeh
Original Contributions

Abstract

Background

Four commercially available intragastric balloons have been used for the management of obesity and underwent randomized controlled trials (RCTs), and we aimed to compare them using a network meta-analysis approach.

Methods

Several databases were queried from inception to May 26, 2017, and we included RCTs enrolling patients treated with Orbera, Heliosphere, ReShape Duo, and Obalon compared with another balloon, sham, or open-label control group. Two investigators independently abstracted data. A random effects frequentist network meta-analysis and relative ranking of agents using surface under the cumulative ranking probabilities were performed.

Results

We included 15 trials at low risk of bias (only two were head-to-head). Compared to control groups, the two fluid-filled devices were associated with significant outcome (% total body weight loss) at 6 months: Orbera, 6.72% (95% CI, 5.55, 7.89) and ReShape Duo 4% (95% CI 2.69, 5.31). Only one of the two gas-filled devices was associated with significant outcome at 6 months: Obalon 3.3% (95% CI 2.30, 4.30), and not the second: Heliosphere 6.71% (95% CI − 0.82, 14.23). Fluid-filled devices had the highest likelihood of superiority in achieving the outcome at 6 months (96.8%) and at 12 months (96.6%). The quality of evidence was high for comparisons against control.

Conclusions

Fluid-filled balloons are more likely to produce weight loss compared to gas-filled balloons or lifestyle intervention. However, they may be associated with a higher rate of intolerance and early removal. This information will aid clinicians in device selection and engaging patients in shared decision-making.

Keywords

Weight loss Bariatric endoscopic therapies Therapeutic endoscopy 

Abbreviations

BMI

Body mass index

CI

Confidence interval

EBTs

Endoscopic bariatric therapies

EWL

Excess weight loss

FDA

Food and Drug Administration

IGBs

Intragastric balloons

RCT

Randomized controlled trial

SAE

Serious adverse events

US

United States

Notes

Author Contributions

Fateh Bazerbachi MD, Samir Haffar MD, M. Hassan Murad MD, MPH, and Barham K. Abu Dayyeh MD, MPH, contributed to the study concept and design, interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and study supervision. Tarek Sawas, Ravinder Jeet Kaur, and Eric J. Vargas contributed to the data acquisition and critical revision of the manuscript for important intellectual content. Larry J. Prokop contributed to the librarian search and critical revision of the manuscript for important intellectual content. Zhen Wang contributed to the statistical analysis and critical revision of the manuscript for important intellectual content.

Compliance with Ethical Standards

Ethical Approval

For this type of study, formal consent is not required.

Conflict of Interest

Fateh Bazerbachi: none, Samir Haffar: none, Tarek Sawas: none, Eric J. Vargas: none, Ravinder Jeet Kaur: none, Zhen Wang: none, Larry Prokop: none, M. Hassan Murad: none, Barham K. Abu Dayyeh received research grants by Spatz Medical and Apollo Endosurgery.

Supplementary material

11695_2018_3227_MOESM1_ESM.docx (43 kb)
ESM 1 (DOCX 43.4 kb)
11695_2018_3227_Fig5_ESM.gif (105 kb)
Supplemental Fig. 1

(GIF 104 kb)

11695_2018_3227_MOESM2_ESM.tif (227 kb)
High Resolution Image (TIFF 227 kb)

References

  1. 1.
    Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–w31.CrossRefGoogle Scholar
  3. 3.
    Vargas EJ, Rizk M, Bazerbachi F, et al. Medical devices for obesity treatment: endoscopic bariatric therapies. Med Clin North Am. 2018;102(1):149–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Bazerbachi F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic bariatric therapies as an obesity intervention. Clin Endosc. 2017;50(1):42–50.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Cummings DE, Overduin J. Gastrointestinal regulation of food intake. J Clin Investig. 2007;117(1):13.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: results of a prospective study. Obesity. 2016;24(9):1849–53.CrossRefPubMedGoogle Scholar
  7. 7.
    Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Hutton B, Salanti G, Chaimani A, et al. The quality of reporting methods and results in network meta-analyses: an overview of reviews and suggestions for improvement. PLoS One. 2014;9(3):e92508.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41.CrossRefPubMedGoogle Scholar
  10. 10.
    Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health. 2011;14(4):417–28.CrossRefPubMedGoogle Scholar
  11. 11.
    Huwaldt JA. Plot Digitizer 2.4. 1. Free software distributed from: http://sourceforge.net/projects/plotdigitizer. 2005.
  12. 12.
    Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. Res Synth Methods. 2012;3(2):111–25.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dias S, Welton N, Caldwell D, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29(7–8):932–44.CrossRefPubMedGoogle Scholar
  15. 15.
    Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64(2):163–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Puhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.CrossRefPubMedGoogle Scholar
  17. 17.
    Brignardello-Petersen R, Bonner A, Alexander PE, et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018;93:36–44.CrossRefPubMedGoogle Scholar
  18. 18.
    Lindor KD, Hughes Jr RW, Ilstrup DM, et al. Intragastric balloons in comparison with standard therapy for obesity—a randomized, double-blind trial. Mayo Clin Proc. 1987;62(11):992–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Benjamin SB, Maher KA, Cattau Jr EL, et al. Double-blind controlled trial of the Garren-Edwards gastric bubble: an adjunctive treatment for exogenous obesity. Gastroenterology. 1988;95(3):581–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Hogan RB, Johnston JH, Long BW, et al. A double-blind, randomized, sham-controlled trial of the gastric bubble for obesity. Gastrointest Endosc. 1989;35(5):381–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Ramhamadany EM, Fowler J, Baird IM. Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989;30(8):1054–7.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rigaud D, Trostler N, Rozen R, et al. Gastric distension, hunger and energy intake after balloon implantation in severe obesity. Int J Obes Relat Metab Disord. 1995;19(7):489–95.PubMedGoogle Scholar
  23. 23.
    Mathus-Vliegen EMH, Tytgat GNJ. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61(1):19–27.CrossRefPubMedGoogle Scholar
  24. 24.
    Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30(1):129–33.CrossRefGoogle Scholar
  25. 25.
    Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. [Erratum appears in Obes Surg. 2007 Jul;17(7):996]. Obes Surg. 2007;17(5):649–57.CrossRefPubMedGoogle Scholar
  26. 26.
    Konopko-Zubrzycka M, Baniukiewicz A, Wroblewski E, et al. The effect of intragastric balloon on plasma ghrelin, leptin, and adiponectin levels in patients with morbid obesity. J Clin Endocrinol Metab. 2009;94(5):1644–9.CrossRefPubMedGoogle Scholar
  27. 27.
    De Castro ML, Morales MJ, Del Campo V, et al. Efficacy, safety, and tolerance of two types of intragastric balloons placed in obese subjects: a double-blind comparative study. Obes Surg. 2010;20(12):1642–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Genco A, Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intragastric balloon followed by another balloon: a prospective study on 100 patients. Obes Surg. 2010;20(11):1496–500.CrossRefPubMedGoogle Scholar
  29. 29.
    Farina MG, Baratta R, Nigro A, et al. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. Obes Surg. 2012;22(4):565–71.CrossRefPubMedGoogle Scholar
  30. 30.
    Giardiello C, Borrelli A, Silvestri E, et al. Air-filled vs water-filled intragastric balloon: a prospective randomized study. Obes Surg. 2012;22(12):1916–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee Y-M, Low HC, Lim LG, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc. 2012;76(4):756–60.CrossRefPubMedGoogle Scholar
  32. 32.
    Fuller NR, Pearson S, Lau NS, et al. An intragastric balloon in the treatment of obese individuals with metabolic syndrome: a randomized controlled study. Obesity. 2013;21(8):1561–70.CrossRefPubMedGoogle Scholar
  33. 33.
    Genco A, Dellepiane D, Baglio G, et al. Adjustable intragastric balloon vs non-adjustable intragastric balloon: case-control study on complications, tolerance, and efficacy. Obes Surg. 2013;23(7):953–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Mohammed MA, Anwar R, Mansour AH, et al. Effects of intragastric balloon versus conservative therapy on appetite regulatory hormones in obese subjects. Trends Med Res. 2014;9(2):58–80.CrossRefGoogle Scholar
  35. 35.
    Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg. 2015;11(4):874–81.Google Scholar
  36. 36.
    Dargent J, Angella S, Pontette F. Post-operative trajectories in bariatric patients: comprehensive analysis of a consecutive series with an original endoscopic method over two years. Obesite. 2016;11(1):39–46. FrenchGoogle Scholar
  37. 37.
    Courcoulas A, Abu Dayyeh BK, Eaton L, et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes. 2017;41(3):427–33.CrossRefGoogle Scholar
  38. 38.
    Sullivan S, Swain JM, Woodman G. The Obalon swallowable 6-month balloon system is more effective than moderate intensity lifestyle therapy alone: results from a 6-month randomized sham controlled trial. Gastroenterology. 2016;150(4 Suppl 1):S1267.CrossRefGoogle Scholar
  39. 39.
    Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Ikramuddin S, Korner J, Lee W-J, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013;309(21):2240–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Ponce J, Nguyen NT, Hutter M, et al. American Society for Metabolic and Bariatric Surgery estimation of bariatric surgery procedures in the United States, 2011-2014. Surg Obes Relat Dis. 2015;11(6):1199–200.CrossRefPubMedGoogle Scholar
  42. 42.
    Watt KD, Heimbach J, Rizk M, et al., editors. Endoscopic intragastric balloon placement for weight loss in liver transplant candidates. Hepatology. Hoboken: Wiley; 2017.Google Scholar
  43. 43.
    Mathus-Vliegen E, Eichenberger R. Fasting and meal-suppressed ghrelin levels before and after intragastric balloons and balloon-induced weight loss. Obes Surg. 2014;24(1):85–94.CrossRefPubMedGoogle Scholar
  44. 44.
    Delgado-Aros S, Camilleri M, Castillo EJ, et al. Effect of gastric volume or emptying on meal-related symptoms after liquid nutrients in obesity: a pharmacologic study. Clin Gastroenterol Hepatol. 2005;3(10):997–1006.CrossRefPubMedGoogle Scholar
  45. 45.
    Vargas EJ, Pesta CM, Bali A, et al. Single fluid-filled intragastric balloon safe and effective for inducing weight loss in a real-world population. Clin Gastroenterol Hepatol. 2018.  https://doi.org/10.1016/j.cgh.2018.01.046.
  46. 46.
    FDA. Liquid-filled intragastric balloon systems: letter to healthcare providers—potential risks. U.S. Food & Drug Administration.; 2017 [updated 08/10/20171/22/2018]; Available from: https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm570916.htm.
  47. 47.
    Maisel W. The FDA alerts health care providers about potential risks with liquid-filled intragastric balloons. U.S. Food & Drug Administration.; 2017 [1/22/2018]; Available from: https://www.fda.gov/MedicalDevices/ResourcesforYou/HealthCareProviders/ucm540655.htm.
  48. 48.
    Dayyeh BKA, Kumar N, Edmundowicz SA, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015;82(3):425–38. e5.CrossRefPubMedGoogle Scholar
  49. 49.
    Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142(4):621–35.CrossRefPubMedGoogle Scholar
  50. 50.
    Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2017.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Fateh Bazerbachi
    • 1
  • Samir Haffar
    • 2
  • Tarek Sawas
    • 1
  • Eric J. Vargas
    • 1
  • Ravinder Jeet Kaur
    • 1
  • Zhen Wang
    • 3
  • Larry J. Prokop
    • 4
  • M. Hassan Murad
    • 3
  • Barham K. Abu Dayyeh
    • 1
  1. 1.Division of Gastroenterology and HepatologyMayo ClinicRochesterUSA
  2. 2.Digestive Center for Diagnosis and TreatmentDamascusSyrian Arab Republic
  3. 3.Mayo Clinic Evidence-based Practice Center, Mayo ClinicRochesterUSA
  4. 4.Department of Library ServicesMayo ClinicRochesterUSA

Personalised recommendations